Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Drugs In Development, 2024 report and make more profitable business decisions.
Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female sex, hereditary disease that affects the adrenal glands, age, and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in the chest and abdomen, early signs of puberty in children, and increased facial and body hair (particularly in females) and deepened voice in females.
The Adrenocortical Carcinoma (Adrenal Cortex Cancer) drugs in development market research report provide comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Adrenocortical Carcinoma (Adrenal Cortex Cancer) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 23 molecules, with 20 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Adrenocortical Carcinoma (Adrenal Cortex Cancer) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Adrenocortical Carcinoma (Adrenal Cortex Cancer) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ADC Therapeutics SAAprea Therapeutics Inc
Basilea Pharmaceutica International Ltd
Bristol-Myers Squibb Co
Corcept Therapeutics Inc
Cytovation AS
Eisai Co Ltd
Enterome Bioscience SA
Exelixis Inc
Fusion Pharmaceuticals Inc
Infinity Pharmaceuticals Inc
Memorial Sloan Kettering Cancer Center
Merck & Co Inc
Merck KGaA
Orphagen Pharmaceuticals Inc
Pharma Mar SA
Sanofi
Shanghai Jiao Tong University School of Medicine
St. Jude Children’s Research Hospital Inc
Stcube Inc
Tempest Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions